⌕
Pharming Group · PHAR · Nasdaq
Tenet 41 · Weak
Compare
$12.59−0.08%At closeTenet 41 · Weak
$12.59−0.01 (−0.08%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD

Pharming Group (PHAR) Earnings Forecast

Analysts expect Pharming Group (PHAR) to earn $0.35 a share in FY26, the average of 2 estimates as of Nov 16, 2026.

Sources Analyst estimates EstimatesConsensus as of How we compute thisNot investment advice
FY26 consensus EPS
$0.35
2 analysts
FY27 consensus EPS
$0.36
2 analysts · low $0.31, high $0.41
EPS revisions, 30 days
+50.3%
$0.23 to $0.35
Disagreement, FY26
50.0%
high to low, $0.26 to $0.44

Consensus estimates only. Analysts' price forecasts and ratings are not licensed here.

Consensus as of Nov 16, 2026 · we check it nightly

Analysts expect Pharming Group to earn $0.56 a share in FY30, growing about 12% a year; 1 analyst publishes an estimate for FY30.

Forward P/E · FY26E
35.7×
$12.59 (at last close) ÷ $0.35 consensus EPS
Coverage · FY26
2 · 3
EPS estimates · revenue estimates

Are estimates going up or down lately?

The FY26 EPS consensus is $0.35, up 53.8% in 90 days. Every figure compares one fiscal period at both ends.

EPS consensus, change over the last 90 days. One step per nightly change.

−33.7%+16.7%+67.1%FY26 +53.8%FY27 +37.8%Aug 18Nov 16
EPS30 days90 daysshown aboveSince Jul 10
FY262 analysts▲ +50.3%$0.23 to $0.35▲ +53.8%$0.23 to $0.35▲ +53.0%$0.23 to $0.35
FY272 analysts▲ +72.9%$0.21 to $0.36▲ +37.8%$0.26 to $0.36▲ +25.5%$0.29 to $0.36
Dec '262 analysts▼ −33.2%$0.14 to $0.10▼ −4.6%$0.10 to $0.10▼ −4.6%$0.10 to $0.10
Mar '271 analyst1 of 30 days0.0% so far1 of 90 days0.0% so far◆ 0.0%$−0.10 to $−0.10

Contributors at both ends of the window: FY26 2 and 2. A change in the average can come from a new contributor as much as from a changed mind, so both counts stay in view.

Measured between two of our own nightly snapshots of one fiscal period, so a new fiscal year entering the view is never read as a revision. Never backfilled. A window still filling says how many days it holds; a blank one means our record is not that long yet.

If the Street is right, what does that imply for the share price?

Price at last close · consensus as of Nov 16, 2026

At 17.8 times earnings, its average over the last five fiscal years, the FY27 consensus of $0.36 works out to $6 a share.

Consensus EPS · FY27
$0.36
2 analysts · low $0.31, high $0.41 · thin coverage
Multiple · five-year average P/E
17.8×
Average of the fiscal-year P/Es, FY18 to FY22.
×
Receipt · PHAR · FY27Nov 16, 2026
Implied, a share
$6

Range on the low and high estimate: $5 to $7.

$5 low$7 high
0.36 × 17.8, to the dollar
Drag the multipleShaded: where Pharming Group's P/E sat at each fiscal year end, FY18 to FY22. Each dot is one year.
5×10×20×30×40×50×58×
5-yr avg 17.8×$6 a share

Each point on the line is a multiple, and the flag is the price it implies for FY27. Past multiples are context, not a guide to future ones.

This is multiplication, not a forecast. It assumes the market pays the multiple you chose and that the consensus is right. Both are often wrong.

You are paying 35.7 times the FY26 consensus for earnings the Street expects to grow about 32% a year to FY28. That is 1.1 times the growth rate.Show today's multiple against its own recordHide the multiple record
Trailing P/E at each fiscal year end, FY18 to FY22 · over 5 fiscal years, with 1 year of near-zero earnings left out. The mark is the median of the last 5.
3,147.5× today
0.3× low52.3× high
0.4× median
Forward 35.7× is a different measure, so it is not placed on a trailing record. Today's mark is the trailing 3,147.5×, on the same basis as every year behind it.

How much do analysts disagree?

For FY30, estimates run from $0.55 to $0.58 around an average of $0.56, drawn by 1 analyst.

FY26E2 analysts
$0.26 to $0.44 · 50.0%
FY27E2 analysts
$0.31 to $0.41 · 28.8%
FY28E1 analyst
$0.60 to $0.64 · 6.7%
FY29E1 analyst
$0.52 to $0.55 · 6.7%
FY30E1 analyst
$0.55 to $0.58 · 6.7%

The dashed line is FY25 filed $0.00, on the GAAP basis.

A wide spread is disagreement, not risk; a narrow one is agreement, not accuracy. Later years are always wider because fewer people forecast them. Bars in amber rest on fewer than 15 analysts. The tick on each bar is the average.

Is next quarter a high bar or an easy one?

Analysts expect Pharming Group to earn $0.10 a share in the December quarter, the average of 2 estimates. We hold no expected date for the next report.

Expected report
Not held
No expected date is published for this company's next report, so none is printed here.
Revenue expected · December quarter
$107.5M
3 analysts, 104.8 to 110.3 in $M

For the March quarter, analysts expect a loss of $0.10 a share.

Does Pharming Group usually beat or miss?

We have not been able to check a quarter yet. Our record of estimates for Pharming Group begins on Jul 10, 2026, and a quarter can be checked only when we hold an estimate for it from before the company reported.

We started recording estimates on Jul 10, 2026, so quarters that reported before that date cannot be checked.

Our record, one quarter per report
Dec '26not reported yet
Mar '27
Jun '27
Sep '27
Dec '27
Mar '28
Jun '28
Sep '28
Dec '28
Mar '29
Jun '29
Sep '29
Checked so far
None yet
one more every report
Beat expectations
Nothing to count
the first check lands after the next report
Share price reaction
Not held
there is no checked quarter to measure a reaction for
Typical gap vs estimate
Not yet
shown once 4 quarters are checked

Checked against the company's reported figure (GAAP) and the average estimate we recorded the night before its results release. Where analysts' number is on an adjusted basis, we leave the comparison out rather than force it. We started recording estimates for Pharming Group on Jul 10, 2026, so earlier quarters cannot be checked, and we never fill them in after the fact.

The Street expects sales to grow 4.2% in FY27 and EPS 3.4%. Sales do all of it and the other two take some back: the net margin moves from 6.6% to 6.6%, and the implied share count from about 71.3M to 71.3M, so these numbers assume the count stands still.Show the decomposition and the margin ladderHide the decomposition
FY27 EPS growth, in points
Revenue growth+4.2
Net margin change−0.8
Share count change0.0
EPS growth+3.4
Legs are rounded to a tenth of a point and the largest remainder carries the difference, so they add to the total. Implied shares = consensus net income ÷ consensus EPS, a direction rather than a decimal.
2 analysts publish an EPS estimate for FY26 and 3 publish revenue. Coverage thins with distance: 1 EPS estimate for FY30. Consensus figures are on the Street's basis and filed figures are GAAP; we label the gap, we do not explain it away.Show coverage by year and over timeHide the coverage chart
Analysts by fiscal year · outlined revenue, filled EPS. Amber marks a panel of fewer than 15.
32
FY26E
32
FY27E
11
FY28E
11
FY29E
21
FY30E
The FY26 panel held 3 analysts when our record of it began on Jul 10, 2026 and holds 2 tonight.

The full consensus, year by year

Consensus as of Nov 16, 2026 · filed figures as reported
Revenue · $Bfiled · consensus average · band = low to high
0.10.40.7historyStreet forecastFY22FY25FY30E

Coverage thins with distance: 3 revenue estimates for FY26, 2 for FY30.

Diluted EPS · $filed · consensus average · band = low to high
−0.060.310.67historyStreet forecastFY22FY25FY30E

Out-year bands widen as fewer analysts publish: 2 EPS estimates for FY26, 1 for FY30.

Fiscal yearRevenue $BYoYEPS $YoYEBITDA $BNet inc. $BShares BAnalysts rev · EPSFwd P/E
FY25Filed0.2—0.00————as filed3,147.5×
FY26E0.40.4 to 0.4▲53.1%a0.350.26 to 0.44n/ca0.10.00.073 · 235.7×
FY27E0.40.4 to 0.4▲4.2%0.360.31 to 0.41▲3.4%0.10.00.073 · 234.6×
FY28E0.40.4 to 0.4n/cb0.620.60 to 0.64n/cb0.10.00.071 · 120.4×
FY29E0.50.5 to 0.5▲15.5%0.530.52 to 0.55▼13.5%0.10.00.071 · 123.6×
FY30E0.60.6 to 0.7n/cb0.560.55 to 0.58▲5.0%0.10.00.072 · 122.5×

Average estimate with low to high beneath. Amber counts mark thin coverage and thin rows carry an amber rule. Shares = consensus net income ÷ consensus EPS, a direction rather than a decimal. The filed row's last column is today's price over that year's filed EPS, the one trailing multiple in that column. a This step crosses the seam: last year is a filed GAAP actual and this year is a consensus estimate, so the two are not prepared on one basis. b More than a third of the analyst panel changed between these two years, so the difference of the two averages measures the panel rather than the forecast.

These are consensus estimates: what analysts expect the business to earn, not where they think the stock trades. Coverage thins and the low to high band widens in the out-years. Context, not advice.

Analysts' price forecasts and grades are not licensed here. This page shows forward consensus estimates only: 2 EPS estimates for FY26, 3 for revenue. Not investment advice.

What do analysts expect Pharming Group to earn in FY26?

Analysts expect Pharming Group to earn $0.35 a share in FY26, the average of 2 estimates as of Nov 16, 2026.

What is Pharming Group's earnings forecast for FY27?

The FY27 consensus for Pharming Group is $0.36 a share from 2 analysts, with a low of $0.31 and a high of $0.41, as of Nov 16, 2026.

Have analysts raised Pharming Group's earnings estimates?

Pharming Group's FY26 EPS consensus rose 53.8% in 90 days, from $0.23 to $0.35, as of Nov 16, 2026.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.